RIV Capital Inc.

CNPOF · Other OTC · USD

0,08USD

0,00 (0,00 %)Stand 19. Dez., 20:34

Vortag 0,08

Kennzahlen

Eröffnung
0,07
Vortag
0,08
Tagesspanne
0,07 – 0,08
52 Wochen
0,0621 – 0,169
Volumen
10.100
Ø Volumen
74.898
Börsenwert
10,96 Mio. $
KGV
-0,1
Gewinn je Aktie (TTM)
-0,51
Dividendenrendite
0,0 %
Beta
0,6
Nächste Zahlen
–

Finanzen

USDFY 2022FY 2021FY 2020FY 2019FY 2018
Umsatz2,4 Mio.13,43 Mio.10,1 Mio.8,13 Mio.3,16 Mio.
Herstellungskosten4,37 Mio.53,66 Mio.53,63 Mio.00
Bruttogewinn2,44 Mio.−40,23 Mio.−43,53 Mio.4,87 Mio.54,78 Mio.
Forschung und Entwicklung0−21−900
Vertrieb und Verwaltung18,32 Mio.7,76 Mio.6,09 Mio.13,02 Mio.22,81 Mio.
Operatives Ergebnis−43,99 Mio.−24,37 Mio.−41,96 Mio.8,03 Mio.46,81 Mio.
EBITDA−46,25 Mio.−61,37 Mio.−7,22 Mio.10,38 Mio.72,39 Mio.
Nettogewinn−179,26 Mio.−42,21 Mio.−106,01 Mio.−28,59 Mio.2,93 Mio.
Gewinn je Aktie (verwässert)-1,09-0,30-0,75-0,150,02

Bewertung

Letzte 12 Monate

KGV
-0,1
Kurs-Umsatz-Verhältnis
4,6
Kurs-Buchwert-Verhältnis
0,1
PEG
0,0
Bruttomarge
101,6 %
Operative Marge
−1.835,4 %
Nettomarge
−7.479,1 %
Verschuldungsgrad
1,0
EV/EBITDA
-0,9
Eigenkapitalrendite
−96,0 %
Kapitalrendite (ROIC)
−7,4 %
Free-Cashflow-Rendite
−254,7 %
FY 2022FY 2021FY 2020FY 2019FY 2018
Bruttomarge101,6 %−299,5 %−431,1 %59,9 %1.731,0 %
Operative Marge−1.835,4 %−181,4 %−415,5 %98,8 %1.479,1 %
Nettomarge−7.479,1 %−314,3 %−1.049,8 %−351,7 %92,7 %
KGV-0,1-5,2-3,1-6,0223,4
Kurs-Umsatz-Verhältnis7,216,533,120,9207,6
Kurs-Buchwert-Verhältnis0,20,81,40,82,1
Verschuldungsgrad1,00,30,00,00,0
Liquidität 3. Grades83,783,75,613,114,9
Dividendenrendite0,0 %0,0 %0,0 %0,0 %0,0 %
Unternehmenswert50,08 Mio.−15,95 Mio.232,83 Mio.137,43 Mio.579,32 Mio.
EV/EBITDA-1,10,3-32,213,28,0
Eigenkapitalrendite−164,7 %−15,9 %−43,0 %−13,6 %1,0 %
Kapitalrendite (ROIC)−7,4 %−5,6 %−17,0 %1,8 %12,9 %
Free-Cashflow-Rendite−162,0 %−9,8 %−1,9 %−3,2 %−0,3 %

Wachstum

FY 2022FY 2021FY 2020FY 2019FY 2018
Umsatz−82,2 %+33,0 %+24,2 %+156,9 %−95,5 %
Bruttogewinn+106,1 %+7,6 %−994,4 %−91,1 %−22,5 %
Operatives Ergebnis−80,5 %+41,9 %−622,7 %−82,9 %−22,5 %
Nettogewinn−324,7 %+60,2 %−270,8 %−1.074,4 %+6.794,8 %
Gewinn je Aktie−263,3 %+60,0 %−400,0 %−952,3 %+4.500,0 %
Freier Cashflow−28,4 %−234,4 %−20,3 %−174,0 %−22.240,3 %
Dividende je Aktie0,0 %0,0 %0,0 %0,0 %0,0 %

Analysten

Einstufungen

Gerade nicht verfügbar.

Kursziel

Gerade nicht verfügbar.

Quartalszahlen

Aug. 2024Apr. 2024März 2024Nov. 2023Aug. 2023Juni 2023März 2023Nov. 2022
Gewinn je Aktie · Erwartet––––––––
Gewinn je Aktie · Tatsächlich-0,06-0,04-0,36-0,07-0,07-0,15-0,06-0,82
Abweichung––––––––
Umsatz · Tatsächlich3,79 Mio.2,14 Mio.2,12 Mio.2,3 Mio.1,79 Mio.1,69 Mio.1,89 Mio.1,82 Mio.

Dividenden und Splits

Keine Dividenden gezahlt.

Aktiensplits

  • 20. Sept. 201837:1000

Eigentümer

Institutionen

Gerade nicht verfügbar.

Insider-Geschäfte

–

Vergleichbare Unternehmen

Über das Unternehmen

RIV Capital Inc., previously known as Canopy Rivers Inc., functions as a venture capital firm. Although it employs a flexible investment strategy, engaging with companies from initial seed stages through to commercial sale, it primarily favors Series A to C funding rounds. The company's core focus is the expanding cannabis industry, specifically targeting promising marijuana enterprises. Its investment interests span numerous sub-sectors within the cannabis ecosystem, including agriculture and food sciences, production, processing, pharmaceuticals and biotechnology, software and data, hardware, consumer products and accessories, wellness products, retail and distribution, as well as media and content. The firm also allocates capital to specific product categories such as beverages, capsules and concentrates, edibles, dry flower/pre-rolls, vaporizers and hardware, pet products, and topical applications. Within agriculture and food sciences, RIV Capital supports advancements in plant, soil, food, animal, and environmental sciences. Its production investments encompass various cultivation methods like indoor, greenhouse, outdoor, and nursery cultivation, along with fermentation. In processing, the firm backs activities including harvesting, extraction and purification, packaging, food and beverage processing, and laboratory testing services. For pharmaceuticals and biotechnology, areas of focus include drug discovery and development, diverse delivery methods (e.g., pills, soft gels, tinctures), biosynthetically derived cannabinoids and other molecules, medical devices (e.g., inhalers), and laboratory equipment. Consumer product interests extend to edibles, beverages, inhalables, cosmetics, and accessories for cannabis consumption. In retail and distribution, the firm targets licensed brick-and-mortar stores, pharmacies, online marketplaces, and delivery services. RIV Capital actively pursues investment opportunities on a global scale. While its historical investment amounts have varied from CA$1 million ($0.71 million) to CA$40 million ($28.45 million), typical investments generally fall within the range of CA$5 million ($3.6 million) to CA$10 million ($7.1 million). The firm predominantly seeks to acquire minority stakes and utilizes a variety of investment instruments, such as debt, preferred and common equity, and production-linked royalties. RIV Capital Inc. was established in 2017 and operates from its headquarters in Toronto, Canada.

Führung

  • Matthew Jonathon MundyChief Strategy Officer, General Counsel & Corporate Secretary
  • Edward James Cirillo LucarelliChief Financial Officer
  • Peter HatziioannouCo-Founder & Advisor
  • David E. VautrinChief Retail Officer & Interim Chief Executive Officer
  • Sean McNultyCo-Founder & Advisor
CEO
David E. Vautrin
Mitarbeitende
94
Hauptsitz
Toronto, ON, CA
Sektor
Healthcare
Branche
Drug Manufacturers - Specialty & Generic
Börsengang
20. Sept. 2018

Nachrichten

Gerade keine Nachrichten zu diesem Unternehmen.

Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.